News
VIR
11.09
-3.57%
-0.41
Vir Biotechnology (VIR) Receives a Rating Update from a Top Analyst
TipRanks · 3d ago
Weekly Report: what happened at VIR last week (0914-0918)?
Weekly Report · 3d ago
Weekly Report: what happened at VIR last week (0907-0911)?
Weekly Report · 09/14 10:21
Weekly Report: what happened at VIR last week (0831-0904)?
Weekly Report · 09/07 10:15
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Barchart · 08/31 15:05
Weekly Report: what happened at VIR last week (0824-0828)?
Weekly Report · 08/31 10:22
Weekly Report: what happened at VIR last week (0817-0821)?
Weekly Report · 08/24 10:23
Vir Biotechnology’s HBV Combo Vaccine Study Reaches Completion, Setting Up Key Pipeline Catalyst
TipRanks · 08/19 16:30
Vir Biotechnology on Track for Record Winning Streak -- Data Talk
Dow Jones · 08/19 15:08
Vir Biotechnology’s Earnings Call Signals Data-Driven Momentum
TipRanks · 08/18 00:18
The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability
Simply Wall St · 08/17 12:22
Weekly Report: what happened at VIR last week (0810-0814)?
Weekly Report · 08/17 10:24
Vir Biotechnology (VIR) Q2 Profit Turn Raises The Question Of Whether Shares Are Still Cheap
Simply Wall St · 08/15 12:21
Olema Appoints Jason O'Byrne As CFO
NASDAQ · 08/13 11:17
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript
The Motley Fool · 08/12 21:28
Analyst Reiterates Buy on Vir Biotechnology, Maintains $20 Price Target Amid Strong Late-Stage HDV Momentum and Solid Cash Runway
TipRanks · 08/10 10:35
Weekly Report: what happened at VIR last week (0803-0807)?
Weekly Report · 08/10 10:18
What Vir Biotechnology (VIR)'s Profit Swing But Earnings Miss Means For Shareholders
Simply Wall St · 08/08 07:37
Vir Biotechnology (VIR) Could Be 58% Below Fair Value On Q2 Profit Turnaround
Simply Wall St · 08/06 12:30
Vir Biotechnology price target lowered to $25 from $27 at Morgan Stanley
TipRanks · 08/06 11:28
More
Webull provides a variety of real-time VIR stock news. You can receive the latest news about Vir Biotechnology, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VIR
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. Its portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers (TCEs) across validated targets in solid tumor indications. It also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Its key product candidates include Elebsiran (VIR-2218); Tobevibart (VIR-3434); VIR-5818; VIR-5525, and VIR-5500. These molecules leverage the PRO-XTEN masking technology with TCEs targeting CD3 on T-cells and HER2, PSMA and EGFR, respectively, on tumor cells. Elebsiran is an investigational hepatitis B virus (HBV)-targeted small interfering RNA that reduces hepatitis B surface antigen (HBsAg). Tobevibart is an investigational neutralizing monoclonal antibody that has been engineered for immune engagement and targets a conserved region on the HBsAg.